Durham-based Inspire Pharmaceuticals (www.inspirepharm.com), a biopharmaceutical company, has launched Phase III clinical trials of epinastine, a proposed nasal spray for treatment of allergies. The testing is designed to determine the efficacy of the spray to affect runny nose, itchy nose and sneezing as well as other symptoms. Results of the trials are expected in the second quarter of 2008. The company licensed rights to the drug from Boehringer Ingelheim International GmbH in 2006.
Inspire Pharmaceuticals is a CED member.